Literature DB >> 9688023

Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii.

S Bassetti1, R Frei, W Zimmerli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9688023     DOI： 10.1016/s0002-9343(98)00133-8

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  17 in total

1.  Use of probiotics in gastrointestinal disorders: what to recommend?

Authors:  Elizabeth C Verna; Susan Lucak
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

2.  Genome-wide association analysis of clinical vs. nonclinical origin provides insights into Saccharomyces cerevisiae pathogenesis.

Authors:  L A H Muller; J E Lucas; D R Georgianna; J H McCusker
Journal:  Mol Ecol       Date:  2011-08-31       Impact factor: 6.185

Review 3.  Risk and safety of probiotics.

Authors:  Shira Doron; David R Snydman
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

Review 4.  Drug-induced diarrhoea.

Authors:  O Chassany; A Michaux; J F Bergmann
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

5.  Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae.

Authors:  Laura Edwards-Ingram; Paul Gitsham; Nicola Burton; Geoff Warhurst; Ian Clarke; David Hoyle; Stephen G Oliver; Lubomira Stateva
Journal:  Appl Environ Microbiol       Date:  2007-02-09       Impact factor: 4.792

Review 6.  Probiotics in clostridium difficile Infection.

Authors:  Xi Na; Ciaran Kelly
Journal:  J Clin Gastroenterol       Date:  2011-11       Impact factor: 3.062

Review 7.  Saccharomyces boulardii in childhood.

Authors:  Yvan Vandenplas; Oscar Brunser; Hania Szajewska
Journal:  Eur J Pediatr       Date:  2008-12-19       Impact factor: 3.183

8.  Microsatellite analysis of genetic diversity among clinical and nonclinical Saccharomyces cerevisiae isolates suggests heterozygote advantage in clinical environments.

Authors:  Ludo A H Muller; John H McCusker
Journal:  Mol Ecol       Date:  2009-05-20       Impact factor: 6.185

Review 9.  Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism.

Authors:  Marco Cassone; Pietro Serra; Francesca Mondello; Antonietta Girolamo; Sandro Scafetti; Eleonora Pistella; Mario Venditti
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

10.  Fatal Saccharomyces cerevisiae aortic graft infection.

Authors:  Davey Smith; David Metzgar; Christopher Wills; Joshua Fierer
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.